Lesson plan
HPH-15
HPH-15 is an antifibrotic drug with higher AMPK-activation activity than metformin. The cellular target of this compound is still being investigated, but binding and knockout studies suggest that it is heterogeneous nuclear ribonucleoprotein U. By binding to this nuclear ribonucleoprotein the expression of many proteins can be affected indirectly, by changing mRNA processing.
Article summary
HPH-15 is an antifibrotic drug with higher AMPK-activation activity than metformin. The cellular target of this compound is still being investigated, but binding and knockout studies suggest that it is heterogeneous nuclear ribonucleoprotein U. By binding to this nuclear ribonucleoprotein the expression of many proteins can be affected indirectly, by changing mRNA processing.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.